Please ensure Javascript is enabled for purposes of website accessibility

What You'll Want to Know About Steris' Solid Q4 Earnings Results

By Keith Speights – May 14, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare company delivered solid growth in Q4 and beat Wall Street estimates on both the top and bottom lines.

The last time Steris (STE 2.28%) announced its quarterly results, investors had some reasons to smile. Revenue increased 5% year over year while adjusted earnings were up by 11%.

Those smiles should have gotten even bigger when Steris announced its Q4 results after the market closed on Monday. Here's what you need to know from the healthcare company's quarterly update.

A man and woman in lab coats and one woman in scrubs looking at a chart.

Image source: Getty Images.

By the numbers

Steris' top-line performance improved in the fourth quarter. Revenue jumped 7% year over year to $768.2 million. Analysts estimated that the company's revenue for the fourth quarter would come in at $738.5 million.

The company's bottom line looked good in the fourth quarter as well. Steris reported net income of $108.7 million, or $1.27 per share, on GAAP basis, compared to $73.6 million, or $0.86 per share, in the same period in 2018.

Steris' adjusted net income in the fourth quarter was $131.1 million, or $1.53 per share. This reflected a 23.9% jump over the prior-year period when the company announced adjusted net income of $105.8 million, or $1.24 per share. It was also better than the consensus analysts' adjusted earnings estimate of $1.43 per share.

Behind the numbers

All four of Steris' business segments performed well in Q4. Healthcare specialty services delivered the strongest growth, with sales jumping 11% to $135.5 million. The company attributed the solid increase to "additional volume and improved productivity."

Healthcare products segment revenue grew 7% year over year to $386.6 million. Increased volume, favorable mix, and operating efficiencies contributed to the segment's performance.

Revenue for Steris' applied sterilization technologies segment increased 7% over the prior-year period to $143.1 million, with growth due primarily to an increase in medical device customer volume. The company's life sciences segment sales grew the least, with sales up 1% year over year to $103 million. Steris stated that growth in consumables and service revenue drove the small revenue increase.

Free cash flow for the company in Q4 increased to $355.4 million compared to $294.3 million in the prior-year period. This increase was primarily due to improved cash from the company's operations, although higher capital expenditures offset this increase somewhat.

Looking ahead

Steris expects that constant currency revenue growth for fiscal 2020 will be between 5% and 6%. The company anticipates adjusted earnings per share (EPS) to be between $5.28 and $5.43.

CEO Walt Rosebrough stated that the company anticipates that fiscal 2020 will be "another record year resulting from underlying demand and new products and services." Steris also expects that cash from operations for fiscal 2020 will grow. The company plans to invest its cash significantly to expand global capacity in its applied sterilization technologies segment.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Steris Plc Stock Quote
Steris Plc
$170.07 (2.28%) $3.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.